- ►milray.org [PDF] - Free from Publisher LC Harrison, MC Honeyman, CE Steele, NL … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 38 individuals, median age 10.8 years,
with antibodies to one or more pancreatic islet antigens (insulin, GAD65, or
tyrosine phosphatase-like insulinoma antigen 2) were randomized to ... Cited by 33 - Related articles - BL Direct - All 8 versions
A Kupila, J Sipilä, P Keskinen, T Simell, M … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 23 - Related articles - BL Direct - All 5 versions
JS Skyler, JP Krischer, J Wolfsdorf, C Cowie … - Diabetes Care, 2005 - bases.bireme.br OBJECTIVE: This randomized, double-masked, placebo-controlled clinical trial
tested whether oral insulin administration could delay or prevent type 1
diabetes in nondiabetic relatives at risk for diabetes. RESEARCH DESIGN AND ... Cited by 110 - Related articles - Cached - All 2 versions
CD Agardh, CM Cilio, ÅL Lethagen, K Lynch, … - Journal of diabetes and its complications, 2005 - Elsevier The purpose of this Phase II study was to evaluate if alum-formulated human
recombinant GAD65 is safe and does not compromise beta cell function. The study
was conducted as a randomized, double blind, placebo-controlled, ... Cited by 71 - Related articles - All 9 versions
DG Alleva, RA Maki, AL Putnam, JM Robinson … - Scandinavian Journal of Immunology, 2006 - interscience.wiley.com NBI-6024 is an altered peptide ligand (APL) corresponding to the 9–23 amino
acid region of the insulin B chain (B (9−23) ), an epitope recognized by
inflammatory interferon-γ-producing T helper (Th)1 lymphocytes in type 1 ... Cited by 20 - Related articles - BL Direct - All 6 versions
- ►jimmunol.org D Homann, T Dyrberg, J Petersen, M Oldstone … - The Journal of Immunology, 1999 - Am Assoc Immnol Oral administration of self-Ags can dampen or prevent autoimmune processes by
induction of bystander suppression. Based on encouraging results from
experiments in nonobese diabetic (NOD) mice, clinical trials have been ... Cited by 51 - Related articles - BL Direct - All 4 versions
L Lazar, R Ofan, N Weintrob, A Avron, M Tamir, … - Diabetes/Metabolism Reviews - interscience.wiley.com Type 1 diabetes mellitus (T1DM) is a T-cell-mediated autoimmune disease that
leads to the destruction of insulin-producing beta cells. Treatment with
DiaPep277, a peptide derived from heat-shock protein 60 (hsp60), has been ... Cited by 22 - Related articles - BL Direct - All 3 versions
LC Harrison, DA Hafler - Current Opinion in Immunology, 2000 - Elsevier Autoimmune diseases result from dysregulated immune responses to self-antigens.
The presence of self-reactive lymphocytes in the blood of healthy individuals [1
and 2] implies that self-antigen-specific regulatory mechanisms are ... Cited by 63 - Related articles - BL Direct - All 3 versions
P Pozzilli, D Pitocco, N Visalli, MG Cavallo, … - Diabetologia, 2000 - Springer The use of insulin, given either subcutaneously or orally, in subjects at risk
for Type I diabetes has been recently introduced in the Diabetes Prevention
Trial of Type I diabetes (DPT-1) trial, a large multinational trial in the ... Cited by 90 - Related articles - BL Direct - All 4 versions
DG Alleva, A Gaur, L Jin, D Wegmann, PA … - Diabetes, 2002 - Am Diabetes Assoc The nonobese diabetic (NOD) mouse is a good model for human type 1 diabetes,
which is characterized by autoreactive T-cell-mediated destruction of
insulin-producing islet β-cells of the pancreas. The 9–23 amino acid ... Cited by 69 - Related articles - BL Direct - All 4 versions
